Description

Cytokinetics’ MYQORZO Launch: Can Early HCM Demand Define The Next Phase?

Cytokinetics reported developments in the first quarter of 2026 centered around the commercial launch of MYQORZO (aficamten) and progress in clinical trials focused on hypertrophic cardiomyopathy (HCM) and heart failure. The launch of MYQORZO in the United States marked the company’s first approved therapy reaching patients, yielding net product revenues of $4.8 million during approximately nine weeks of commercial availability. Early demand and healthcare provider (HCP) engagement exceeded internal expectations, supported by high prescriber awareness and favorable perceptions of MYQORZO’s clinical profile, including dosing flexibility, safety, and absence of drug-drug interaction requirements in the REMS (Risk Evaluation and Mitigation Strategy) program. Over 275 HCPs prescribed MYQORZO in Q1, with more than half from high-volume chronic medical illness prescribers. The company also anticipates launching MYQORZO commercially in Europe, beginning with Germany in Q2, following European Commission approval.